Therefore, mTOR inhibitors could be a “game changer” to reduce the problem of post-transplantation skin cancer, but more research will be necessary to optimise clinical protocols that will be widely acceptable for high-risk patients that can benefit from this general strategy. This evidence concerns the gene MTOR and skin cancer.